IMCR

Immunocore Holdings plc is a commercial-stage biotechnology company that specializes in the discovery, development, and commercialization of T cell receptor (TCR) therapies. Utilizing its proprietary ImmTAX platform, the company develops bispecific therapies targeting various conditions, including multiple cancers, HIV, and HBV. Immunocore's business model focuses on pioneering immunomodulating medicines to improve patient outcomes in cancer, infectious diseases, and autoimmune diseases, and it collaborates with industry and academic partners to enhance its therapeutic offerings.